Scotia Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Scotia Capital’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.8K	Sell	10,000 -16,750	-63%	-$28.2K	﹤0.01%	910
2025 Q4	$44.7K	Hold	26,750	–	–	﹤0.01%	883
2025 Q3	$45.2K	Hold	26,750	–	–	﹤0.01%	894
2025 Q2	$24.3K	Hold	26,750	–	–	﹤0.01%	852
2025 Q1	$12.1K	Hold	26,750	–	–	﹤0.01%	840
2024 Q4	$13.4K	Buy	26,750 +10,000	+60%	+$7.34K	﹤0.01%	849
2024 Q3	$15.2K	Hold	16,750	–	–	﹤0.01%	825
2024 Q2	$16.7K	Hold	16,750	–	–	﹤0.01%	819
2024 Q1	$24.8K	Hold	16,750	–	–	﹤0.01%	818
2023 Q4	$18.3K	Hold	16,750	–	–	﹤0.01%	784
2023 Q3	$19.8K	Hold	16,750	–	–	﹤0.01%	761
2023 Q2	$23.6K	Hold	16,750	–	–	﹤0.01%	771
2023 Q1	$25.1K	Hold	16,750	–	–	﹤0.01%	771
2022 Q4	$19.6K	Sell	16,750 -16,750	-50%	-$21.1K	﹤0.01%	770
2022 Q3	$38K	Hold	33,500	–	–	﹤0.01%	757
2022 Q2	$53K	Sell	33,500 -266	-0.8%	-$351	﹤0.01%	780
2022 Q1	$52K	Buy	33,766 +266	+0.8%	+$413	﹤0.01%	857
2021 Q4	$82K	Sell	33,500 -266	-0.8%	-$623	﹤0.01%	845
2021 Q3	$85K	Buy	33,766 +266	+0.8%	+$682	﹤0.01%	834
2021 Q2	$95K	Hold	33,500	–	–	﹤0.01%	805
2021 Q1	$79K	Sell	33,500 -23	-0.1%	-$55	﹤0.01%	775
2020 Q4	$59K	Buy	33,523 +425	+1%	+$594	﹤0.01%	736
2020 Q3	$31K	Sell	33,098 -402	-1%	-$355	﹤0.01%	692
2020 Q2	$29K	Sell	33,500 -13,000	-28%	-$11.4K	﹤0.01%	613
2020 Q1	$39K	Buy	46,500 +13,000	+39%	+$12.9K	﹤0.01%	617
2019 Q4	$30K	Hold	33,500	–	–	﹤0.01%	723
2019 Q3	$33K	Hold	33,500	–	–	﹤0.01%	707
2019 Q2	$37K	Hold	33,500	–	–	﹤0.01%	710
2019 Q1	$44K	Hold	33,500	–	–	﹤0.01%	682
2018 Q4	$31K	Sell	33,500 -4,791	-13%	-$7.34K	﹤0.01%	643
2018 Q3	$79K	Buy	38,291 +10,287	+37%	+$21.6K	﹤0.01%	695
2018 Q2	$66K	Hold	28,004	–	–	﹤0.01%	650
2018 Q1	$66K	Buy	28,004 +8,173	+41%	+$19.2K	﹤0.01%	682
2017 Q4	$37K	Hold	19,831	–	–	﹤0.01%	701
2017 Q3	$49K	Buy	19,831 +3,200	+19%	+$7.93K	﹤0.01%	682
2017 Q2	$46K	Hold	16,631	–	–	﹤0.01%	669
2017 Q1	$50K	Hold	16,631	–	–	﹤0.01%	714
2016 Q4	$53K	Hold	16,631	–	–	﹤0.01%	783
2016 Q3	$57K	Buy	+16,631	New	+$45.9K	﹤0.01%	761

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scotia Capital's LCTX Position: Q1 2026 in Review

Scotia Capital reduced its Lineage Cell Therapeutics (LCTX) stake by 63% in Q1 2026, selling an estimated $28.2K and leaving 10,000 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #910.

Scotia Capital first reported a position in LCTX in Q3 2016 and has held it in 39 quarters since. The position peaked at $95K in Q2 2021. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

Scotia Capital held 10,000 shares of Lineage Cell Therapeutics worth $15.8K as of Q1 2026.
Scotia Capital sold 16,750 Lineage Cell Therapeutics shares in Q1 2026, an estimated $28.2K.
Lineage Cell Therapeutics made up ﹤0.01% of Scotia Capital's portfolio in Q1 2026, its #910 holding.
Scotia Capital first reported a position in Lineage Cell Therapeutics in Q3 2016 and has held it in 39 quarters since.
Scotia Capital's Lineage Cell Therapeutics position peaked at $95K in Q2 2021.
130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.